Meiji Seika Pharma's Nacubactam Shows Promise in Phase III Trial for Urinary Tract Infections
Event summary
- Meiji Seika Pharma's Phase III Integral-1 trial for nacubactam met primary endpoint, demonstrating non-inferiority to imipenem-cilastatin in treating complicated urinary tract infections (cUTI) or acute uncomplicated pyelonephritis (AP).
- Results published in The Lancet on May 15, 2026, showed cefepime-nacubactam was superior to imipenem-cilastatin, with comparable safety profiles.
- Positive results also observed in Integral-2 trial for carbapenem-resistant Enterobacterales (CRE), with manuscript in preparation.
- Meiji Seika Pharma submitted a manufacturing and marketing approval application for nacubactam in Japan in December 2025.
The big picture
Meiji Seika Pharma's positive Phase III results for nacubactam come at a critical time, as carbapenem-resistant Gram-negative bacteria pose a growing global threat. The company's focus on addressing antimicrobial resistance (AMR) aligns with broader industry efforts to combat the 'silent pandemic.' The success of nacubactam could significantly impact the pharmaceutical landscape, particularly in the treatment of severe infections where options are limited.
What we're watching
- Regulatory Approval
- The pace at which Meiji Seika Pharma secures regulatory approval for nacubactam in Japan and other markets will determine its commercial viability.
- Market Adoption
- Whether nacubactam can gain traction as a treatment for carbapenem-resistant infections, given the urgent global need for effective antimicrobials.
- Competitive Landscape
- How Meiji Seika Pharma positions nacubactam against existing and emerging therapies for multidrug-resistant Gram-negative pathogens.
Related topics